Search results
Results From The WOW.Com Content Network
In 1997, Gideon Richter withdrew from efforts to manufacture mifepristone in the United States following opposition from pro-life groups, which led to Danco filing a breach of contract lawsuit. [ 6 ] On September 28, 2000, Danco Laboratories received approval to distribute mifepristone (under the Mifeprex brand name) from the US Food and Drug ...
Mifepristone was developed in 1980 and came into use in France in 1987. [16] It became available in the United States in 2000, for medication abortion, and in 2010, for Cushing's syndrome. [17] [10] [12] It is on the World Health Organization's List of Essential Medicines. [18] Mifepristone was approved in Canada in January 2017. [19] [20]
Aid Access is a nonprofit organization that provides access to medication abortion by mail to the United States and worldwide. It describes its work as a harm reduction strategy designed to provide safe access to mifepristone and misoprostol for those able to become pregnant in the United States who may not otherwise have access to abortion or miscarriage management services. [2]
The idea of directing the FDA to revoke access to mifepristone is a core policy plan in Project 2025, a 900-plus page document written by conservative groups and organized by the Heritage ...
Metapristone (developmental code name RU-42633; also known as desmethylmifepristone) is the major metabolite of mifepristone (RU-486, RU-38486) and a selective progesterone receptor modulator (SPRM) which itself was never marketed.
Hoeschst AG transferred all rights for medical uses of mifepristone (outside of the United States) to Exelgyn. [2] In 1999, Exelgyn won approval of Mifegyne in 11 additional countries. [3] As of 2024, Exelgyn distributes mifepristone to 40 countries, [4] but within the United States it is distributed by Danco Laboratories and GenBioPro.
[159] [160] [161] Even so, several states in the US require providers of non-surgical abortion who use mifepristone to tell patients that reversal is an option. [162] In 2019, researchers initiated a small trial of the so-called "reversal" regimen using mifepristone followed by progesterone or placebo.
Misoprostol is used for the prevention of NSAID-induced gastric ulcers.It acts upon gastric parietal cells, inhibiting the secretion of gastric acid by G-protein coupled receptor-mediated inhibition of adenylate cyclase, which leads to decreased intracellular cyclic AMP levels and decreased proton pump activity at the apical surface of the parietal cell.